1
|
|
Congress |
34 |
384 |
2
|
Aprile E, Aalbers J, Agostini F, Alfonsi M, Althueser L, Amaro FD, Anthony M, Arneodo F, Baudis L, Bauermeister B, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, de Perio P, Di Gangi P, Di Giovanni A, Diglio S, Elykov A, Eurin G, Fei J, Ferella AD, Fieguth A, Fulgione W, Gallo Rosso A, Galloway M, Gao F, Garbini M, Geis C, Grandi L, Greene Z, Qiu H, Hasterok C, Hogenbirk E, Howlett J, Itay R, Joerg F, Kaminsky B, Kazama S, Kish A, Koltman G, Landsman H, Lang RF, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, Mahlstedt J, Manfredini A, Marrodán Undagoitia T, Masbou J, Masson D, Messina M, Micheneau K, Miller K, Molinario A, Morå K, Murra M, Naganoma J, Ni K, Oberlack U, Pelssers B, Piastra F, Pienaar J, Pizzella V, Plante G, Podviianiuk R, Priel N, Ramírez García D, Rauch L, Reichard S, Reuter C, Riedel B, Rizzo A, Rocchetti A, Rupp N, Dos Santos JMF, Sartorelli G, Scheibelhut M, Schindler S, Schreiner J, Schulte D, Schumann M, Scotto Lavina L, Selvi M, et alAprile E, Aalbers J, Agostini F, Alfonsi M, Althueser L, Amaro FD, Anthony M, Arneodo F, Baudis L, Bauermeister B, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, de Perio P, Di Gangi P, Di Giovanni A, Diglio S, Elykov A, Eurin G, Fei J, Ferella AD, Fieguth A, Fulgione W, Gallo Rosso A, Galloway M, Gao F, Garbini M, Geis C, Grandi L, Greene Z, Qiu H, Hasterok C, Hogenbirk E, Howlett J, Itay R, Joerg F, Kaminsky B, Kazama S, Kish A, Koltman G, Landsman H, Lang RF, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, Mahlstedt J, Manfredini A, Marrodán Undagoitia T, Masbou J, Masson D, Messina M, Micheneau K, Miller K, Molinario A, Morå K, Murra M, Naganoma J, Ni K, Oberlack U, Pelssers B, Piastra F, Pienaar J, Pizzella V, Plante G, Podviianiuk R, Priel N, Ramírez García D, Rauch L, Reichard S, Reuter C, Riedel B, Rizzo A, Rocchetti A, Rupp N, Dos Santos JMF, Sartorelli G, Scheibelhut M, Schindler S, Schreiner J, Schulte D, Schumann M, Scotto Lavina L, Selvi M, Shagin P, Shockley E, Silva M, Simgen H, Thers D, Toschi F, Trinchero G, Tunnell C, Upole N, Vargas M, Wack O, Wang H, Wang Z, Wei Y, Weinheimer C, Wittweg C, Wulf J, Ye J, Zhang Y, Zhu T. Dark Matter Search Results from a One Ton-Year Exposure of XENON1T. PHYSICAL REVIEW LETTERS 2018; 121:111302. [PMID: 30265108 DOI: 10.1103/physrevlett.121.111302] [Show More Authors] [Citation(s) in RCA: 184] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 08/14/2018] [Indexed: 06/08/2023]
Abstract
We report on a search for weakly interacting massive particles (WIMPs) using 278.8 days of data collected with the XENON1T experiment at LNGS. XENON1T utilizes a liquid xenon time projection chamber with a fiducial mass of (1.30±0.01) ton, resulting in a 1.0 ton yr exposure. The energy region of interest, [1.4,10.6] keV_{ee} ([4.9,40.9] keV_{nr}), exhibits an ultralow electron recoil background rate of [82_{-3}^{+5}(syst)±3(stat)] events/(ton yr keV_{ee}). No significant excess over background is found, and a profile likelihood analysis parametrized in spatial and energy dimensions excludes new parameter space for the WIMP-nucleon spin-independent elastic scatter cross section for WIMP masses above 6 GeV/c^{2}, with a minimum of 4.1×10^{-47} cm^{2} at 30 GeV/c^{2} and a 90% confidence level.
Collapse
|
|
7 |
184 |
3
|
Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130:422-7. [PMID: 16042693 DOI: 10.1111/j.1365-2141.2005.05605.x] [Citation(s) in RCA: 160] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
This case-control study investigated the interactions between genetic and environmental factors and inhibitor development in 108 children with haemophilia A exclusively treated with recombinant factor VIII (FVIII). Sixty patients with inhibitors were compared with 48 inhibitor-free controls. Family history of inhibitors and null mutations in the FVIII gene were more prevalent in cases than in controls (20% vs. 2%, P = 0.001 and 83% vs. 64%, P = 0.04, respectively). On the other hand, there was no difference between cases and controls for such putative risk factors of inhibitor development as amniocentesis/villocentesis, premature/caesarean birth, breast-feeding, treatment during infections/vaccinations, surgical procedures and central nervous system bleeding. A trend was found for an increased risk of inhibitor development in children first treated at a young age (<11 months); however, this was not confirmed after adjusting for genetic factors. The implementation of prophylaxis was evaluated as a putative risk factor in a subgroup of 25 cases: seven who started prophylaxis prior to inhibitor development and 18 potentially eligible for prophylaxis because they were inhibitor-free up to the age of 35 months (i.e. the upper limit of the age range at prophylaxis onset in cases and the median age at prophylaxis onset in controls). Patients who started prophylaxis had a lower inhibitor risk than those treated on demand (adjusted odds ratio 0.2, 95% confidence interval 0.06-0.9). The protective effect on inhibitor development shown by prophylaxis may represent an additional advantage prompting its use in haemophilic children.
Collapse
|
|
20 |
160 |
4
|
Kohler B, Yakovlev VV, Che J, Krause JL, Messina M, Wilson KR, Schwentner N, Whitnell RM, Yan Y. Quantum Control of Wave Packet Evolution with Tailored Femtosecond Pulses. PHYSICAL REVIEW LETTERS 1995; 74:3360-3363. [PMID: 10058181 DOI: 10.1103/physrevlett.74.3360] [Citation(s) in RCA: 148] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
|
30 |
148 |
5
|
Abstract
Recent investigations on the effects of phyto-oestrogens on various tissues have revealed that these diverse molecules may improve human health, particularly by protecting against certain chronic diseases. After a brief examination of the food sources, structures, and general cellular actions of the major phyto-oestrogens, current research findings on cardiovascular disease, skeletal tissues, and reproductive cancers are reviewed. Phyto-oestrogen concentrations in blood may be maintained at high levels in those consuming soyabean (Glycine max)-based food daily at several meals and exert their effects on target cells through either genomic effects via the classical oestrogen receptors or non-genomic effects mediated by membrane-bound oestrogen receptors or other cellular proteins. The expression of oestrogen receptor (OR) subtypes alpha (a) and beta (beta) varies across tissues, and cells that preferentially express OR-beta, which may include bone cells, are more likely to respond to phyto-oestrogens. Conversely, reproductive tissues contain relatively more OR-a and may, thus, be differently affected by phyto-oestrogens. Soyabean phyto-oestrogens appear to prevent the progression of atherosclerosis through multiple interactions, including lowering of plasma lipids and lipoproteins, increased vasodilatation and, possibly, decreased activation of blood platelets and vascular smooth muscle cells. However, a favourable impact on cardiovascular disease morbidity and mortality by a soyabean-enriched western-type diet remains to be shown, and unresolved questions remain regarding dose and form of the phyto-oestrogens in relation to risks and benefits. The isoflavones of soyabean have been shown consistently to have bone-retentive effects in animal studies by several investigators using rodent models, although intakes must be above a relatively high threshold level for a lengthy period of time, and little or no extra benefit is observed with intakes above this threshold level. The reports of modest or no effects on prevention of bone loss in human and non-human primate studies respectively, may be due to the limited doses tested so far. The relationship between soyabean-food intake and cancer risk has been more extensively investigated than for any other disease, but with less certainty about the benefits of long-term consumption of phyto-oestrogen-containing foods on prevention of cancer. The observations that breast and prostate cancer rates are lower in Asian countries, where soyabean foods are consumed at high levels, and the high isoflavone content of soyabeans have led to examination of the potential protective effects of phyto-oestrogens. Establishing diet-cancer relationships has proved difficult, in part because of the conflicting data from various studies of effects of soyabean-diets on cancer. Epidemiological evidence, though not impressive, does suggest that soyabean intake reduces breast cancer risk. The isoflavone genistein has a potent effect on breast cancer cells in vitro, and early exposure of animals to genistein has been effective in reducing later development of mammary cancer. Thus, continuous consumption of soyabean foods in early life and adulthood may help explain the low breast cancer mortality rates in Asian countries. Although the evidence for a protective effect against prostate cancer may be slightly more supportive, more research is needed before any firm conclusions can be made about the phyto-oestrogen-cancer linkages.
Collapse
|
Journal Article |
16 |
115 |
6
|
Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, Diana M. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 2006; 83:163-8. [PMID: 16343811 DOI: 10.1016/j.drugalcdep.2005.11.008] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2005] [Revised: 11/09/2005] [Accepted: 11/09/2005] [Indexed: 10/25/2022]
Abstract
Cognitive dysfunction is a major feature of drug addiction. In the present paper, we compared the decision-making ability using the Iowa gambling task of methadone- and buprenorphine-maintained individuals to non opiate-dependent drug-free controls. Buprenorphine-maintained individuals performed better than methadone-maintained individuals, and not differently than non opiate-dependent controls. In addition, methadone-maintained individuals had more perseverative errors on the Wisconsin card sorting task (WCST) as compared with non opiate-dependent drug-free controls whereas buprenorphine-maintained individuals had intermediate scores. Scores on Weschler adult intelligence scale (WAIS-R) were similar for methadone- and buprenorphine-maintained individuals whereas drug-free controls had significantly higher scores. In addition, both opiate-dependent groups performed more poorly than drug-free controls on the Benton visual retention test (BVRT). The results suggest that buprenorphine in contrast to methadone improves decision-making, and thus may be more effective in rehabilitation programs of opiate-dependent subjects and this improvement may be related to its distinct pharmacological action as a k antagonist.
Collapse
|
|
19 |
103 |
7
|
Aprile E, Aalbers J, Agostini F, Alfonsi M, Amaro FD, Anthony M, Arneodo F, Barrow P, Baudis L, Bauermeister B, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Bütikofer L, Calvén J, Cardoso JMR, Cervantes M, Cichon D, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, de Perio P, Di Gangi P, Di Giovanni A, Diglio S, Eurin G, Fei J, Ferella AD, Fieguth A, Fulgione W, Gallo Rosso A, Galloway M, Gao F, Garbini M, Gardner R, Geis C, Goetzke LW, Grandi L, Greene Z, Grignon C, Hasterok C, Hogenbirk E, Howlett J, Itay R, Kaminsky B, Kazama S, Kessler G, Kish A, Landsman H, Lang RF, Lellouch D, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, Manfredini A, Mariş I, Marrodán Undagoitia T, Masbou J, Massoli FV, Masson D, Mayani D, Messina M, Micheneau K, Molinario A, Morå K, Murra M, Naganoma J, Ni K, Oberlack U, Pakarha P, Pelssers B, Persiani R, Piastra F, Pienaar J, Pizzella V, Piro MC, Plante G, Priel N, Rauch L, Reichard S, Reuter C, Riedel B, Rizzo A, Rosendahl S, Rupp N, Saldanha R, Dos Santos JMF, Sartorelli G, Scheibelhut M, et alAprile E, Aalbers J, Agostini F, Alfonsi M, Amaro FD, Anthony M, Arneodo F, Barrow P, Baudis L, Bauermeister B, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Bütikofer L, Calvén J, Cardoso JMR, Cervantes M, Cichon D, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, de Perio P, Di Gangi P, Di Giovanni A, Diglio S, Eurin G, Fei J, Ferella AD, Fieguth A, Fulgione W, Gallo Rosso A, Galloway M, Gao F, Garbini M, Gardner R, Geis C, Goetzke LW, Grandi L, Greene Z, Grignon C, Hasterok C, Hogenbirk E, Howlett J, Itay R, Kaminsky B, Kazama S, Kessler G, Kish A, Landsman H, Lang RF, Lellouch D, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, Manfredini A, Mariş I, Marrodán Undagoitia T, Masbou J, Massoli FV, Masson D, Mayani D, Messina M, Micheneau K, Molinario A, Morå K, Murra M, Naganoma J, Ni K, Oberlack U, Pakarha P, Pelssers B, Persiani R, Piastra F, Pienaar J, Pizzella V, Piro MC, Plante G, Priel N, Rauch L, Reichard S, Reuter C, Riedel B, Rizzo A, Rosendahl S, Rupp N, Saldanha R, Dos Santos JMF, Sartorelli G, Scheibelhut M, Schindler S, Schreiner J, Schumann M, Scotto Lavina L, Selvi M, Shagin P, Shockley E, Silva M, Simgen H, Sivers MV, Stein A, Thapa S, Thers D, Tiseni A, Trinchero G, Tunnell C, Vargas M, Upole N, Wang H, Wang Z, Wei Y, Weinheimer C, Wulf J, Ye J, Zhang Y, Zhu T. First Dark Matter Search Results from the XENON1T Experiment. PHYSICAL REVIEW LETTERS 2017; 119:181301. [PMID: 29219593 DOI: 10.1103/physrevlett.119.181301] [Show More Authors] [Citation(s) in RCA: 97] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Indexed: 06/07/2023]
Abstract
We report the first dark matter search results from XENON1T, a ∼2000-kg-target-mass dual-phase (liquid-gas) xenon time projection chamber in operation at the Laboratori Nazionali del Gran Sasso in Italy and the first ton-scale detector of this kind. The blinded search used 34.2 live days of data acquired between November 2016 and January 2017. Inside the (1042±12)-kg fiducial mass and in the [5,40] keV_{nr} energy range of interest for weakly interacting massive particle (WIMP) dark matter searches, the electronic recoil background was (1.93±0.25)×10^{-4} events/(kg×day×keV_{ee}), the lowest ever achieved in such a dark matter detector. A profile likelihood analysis shows that the data are consistent with the background-only hypothesis. We derive the most stringent exclusion limits on the spin-independent WIMP-nucleon interaction cross section for WIMP masses above 10 GeV/c^{2}, with a minimum of 7.7×10^{-47} cm^{2} for 35-GeV/c^{2} WIMPs at 90% C.L.
Collapse
|
|
8 |
97 |
8
|
Sibley LD, Messina M, Niesman IR. Stable DNA transformation in the obligate intracellular parasite Toxoplasma gondii by complementation of tryptophan auxotrophy. Proc Natl Acad Sci U S A 1994; 91:5508-12. [PMID: 8202518 PMCID: PMC44025 DOI: 10.1073/pnas.91.12.5508] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The protozoan parasite Toxoplasma gondii infects a wide range of vertebrate hosts and is an important opportunistic pathogen in immunocompromised humans. Although Toxoplasma is amenable to both biochemical and cellular experimental approaches, the molecular basis of its success as an intracellular parasite is poorly understood. To provide a system for molecular genetic analyses, we have developed a stable DNA transformation system for Toxoplasma based on complementation of its naturally occurring tryptophan auxotrophy. Complementation was accomplished by expressing the Escherichia coli trpB gene, encoding the beta subunit of tryptophan synthase (EC 4.2.1.20), the enzyme that catalyzes the formation of tryptophan from indole plus serine. Transformants were obtained by electroporation of a plasmid, called SAG1/trpB, containing the trpB gene flanked by Toxoplasma surface antigen 1 (SAG1) gene sequences and selection for growth on indole. Transformants were obtained with circular forms of the SAG1/trpB plasmid with efficiencies of 10(-4) per cell. Transformation with either circular or linear SAG1/trpB resulted in integration into the genome at distinct, nonhomologous sites. Trp+ transformants typically contained tandemly repeated copies of the SAG1/trpB plasmid and were stable in the absence of continued selection. The Trp phenotype provides a dominant selectable marker that should allow expression of foreign or altered genes in Toxoplasma and facilitate molecular analyses of genes important for intracellular survival.
Collapse
|
research-article |
31 |
93 |
9
|
Messina M, Niesman I, Mercier C, Sibley LD. Stable DNA transformation of Toxoplasma gondii using phleomycin selection. Gene 1995; 165:213-7. [PMID: 8522178 DOI: 10.1016/0378-1119(95)00548-k] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Toxoplasma gondii (Tg) is an obligate intracellular protozoan parasite that is an important opportunistic pathogen in humans. To provide additional tools for molecular genetic analysis, we have developed a set of vectors for DNA transformation in Tg based on selection with the antibiotic phleomycin (Ph). These new vectors rely on the flanking sequences from the parasite genes GRA1, GRA2 or SAG1 to drive expression of the Tn5 ble gene encoding resistance to the DNA intercalating drug Ph (PhR). Treatment of extracellular parasites was used to select stable PhR transformants by plaque formation on host cell monolayers. Transfection of linear or circular forms of the pGRA1/ble, pGRA2/ble or pSAG1/ble vectors by electroporation resulted in stable transformation with an efficiency of approx. 10(-4)/micrograms DNA. Stable transformants contained 1-5 copies of ble that were integrated at non-homologous sites in the parasite nuclear genome. Ble provides a new dominant selectable marker for safe, efficient and rapid isolation of stable DNA transformants in Tg.
Collapse
|
|
30 |
83 |
10
|
Messina M, Bennink M. Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. BAILLIERE'S CLINICAL ENDOCRINOLOGY AND METABOLISM 1998; 12:707-28. [PMID: 10384821 DOI: 10.1016/s0950-351x(98)80012-8] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Soy foods and soybean components have received considerable attention of late for their potential role in reducing cancer risk. Although the relationship between soy intake and the risk of breast and prostate cancer has been the focus of most interest, the relationship between soy intake and other cancers, including colorectal cancer, has also been studied. Several anti-carcinogens have been identified in soybeans, but most enthusiasm for the potential anti-cancer effects of soy undoubtedly stems from work involving soybean isoflavones. Isoflavones have a limited distribution in nature, and, for practical purposes, soyfoods are the only nutritionally relevant dietary source of these phytochemicals. Isoflavones are weak oestrogens but possess other potentially important biological attributes independent of their ability to bind to the oestrogen receptor. The isoflavone genistein inhibits the growth of most types of hormone-dependent and hormone-independent cancer cells in vitro, including colonic cancer cells. Several mechanisms for the in vitro anti-cancer effects of genistein have been proposed, including effects on signal transduction. A number of epidemiological studies, primarily of Asian origin, have examined the relationship between soy intake and the risk of colorectal cancer. Although these studies provide little support for a protective effect of soy, concerns have been raised about the completeness of the soy intake data, since soy was not the focus of these studies and most of this research was conducted prior to the recent interest in the anti-cancer effects of soy. The effect of soy/isoflavone intake has also been studied in rodents, but again these data are conflicting and provide only modest support for a protective effect. Although the relationship between soy intake and colonic cancer risk is certainly worthy of further investigation, there is, at the moment, very limited support for soy exerting a protective effect against this type of cancer.
Collapse
|
Review |
27 |
74 |
11
|
Cutrignelli MI, Messina M, Tulli F, Randazzo B, Olivotto I, Gasco L, Loponte R, Bovera F. Evaluation of an insect meal of the Black Soldier Fly (Hermetia illucens) as soybean substitute: Intestinal morphometry, enzymatic and microbial activity in laying hens. Res Vet Sci 2018; 117:209-215. [PMID: 29304440 DOI: 10.1016/j.rvsc.2017.12.020] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Revised: 12/20/2017] [Accepted: 12/26/2017] [Indexed: 11/18/2022]
Abstract
This research investigated the ileum morphometry and enzymatic activity, the caecal volatile fatty acid production and the apparent nutrient digestibility in laying hens fed a Hermetia illucens larvae meal (HILM) as a complete replacement of diet soybean meal (SBM). The hens fed HILM exhibited a lower live weight (P<0.05) and a higher incidence of the full digestive tract (P<0.05) than the SBM group. In the duodenum, the maltase exhibited a higher (P<0.05) activity in the HILM group while the intestinal alkaline phosphatase (IAP) had a higher (P<0.05) activity in the SBM group. In the ileum, the maltase and saccarase had a higher activity in the HILM hens (P≤0.01) while the IAP and ɤ glutamil transferase had a higher activity in the SBM group (P<0.05 and P<0.01, respectively). The HILM group showed a higher (P<0.05) villi height in the duodenum, while the opposite happened in the jejunum and the ileum. Only in the ileum the crypt depth resulted higher (P<0.05) in the HIML group than in the SBM. The higher production of acetate (P<0.05) and butyrate (P<0.01) affected the total production of volatile fatty acids of the HILM group. The coefficient of apparent digestibility of dry and organic matter as well as of crude protein was higher (P<0.05) in SBM group. The total replacement of SBM with HILM in laying hens diet from 24 to 45weeks of age resulted in a higher caecal production of butyric acid while the enzymatic activities of brush border membrane were partially reduced.
Collapse
|
|
7 |
72 |
12
|
Aprile E, Aalbers J, Agostini F, Alfonsi M, Althueser L, Amaro FD, Antochi VC, Angelino E, Arneodo F, Barge D, Baudis L, Bauermeister B, Bellagamba L, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, de Perio P, Depoian A, Di Gangi P, Di Giovanni A, Diglio S, Elykov A, Eurin G, Fei J, Ferella AD, Fieguth A, Fulgione W, Gaemers P, Gallo Rosso A, Galloway M, Gao F, Garbini M, Grandi L, Greene Z, Hasterok C, Hils C, Hogenbirk E, Howlett J, Iacovacci M, Itay R, Joerg F, Kazama S, Kish A, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, López Fune E, Macolino C, Mahlstedt J, Manfredini A, Marignetti F, Marrodán Undagoitia T, Masbou J, Mastroianni S, Messina M, Micheneau K, Miller K, Molinario A, Morå K, Mosbacher Y, Murra M, Naganoma J, Ni K, Oberlack U, Odgers K, Palacio J, Pelssers B, Peres R, Pienaar J, Pizzella V, Plante G, Podviianiuk R, Qin J, Qiu H, Ramírez García D, Reichard S, Riedel B, Rocchetti A, Rupp N, et alAprile E, Aalbers J, Agostini F, Alfonsi M, Althueser L, Amaro FD, Antochi VC, Angelino E, Arneodo F, Barge D, Baudis L, Bauermeister B, Bellagamba L, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, de Perio P, Depoian A, Di Gangi P, Di Giovanni A, Diglio S, Elykov A, Eurin G, Fei J, Ferella AD, Fieguth A, Fulgione W, Gaemers P, Gallo Rosso A, Galloway M, Gao F, Garbini M, Grandi L, Greene Z, Hasterok C, Hils C, Hogenbirk E, Howlett J, Iacovacci M, Itay R, Joerg F, Kazama S, Kish A, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, López Fune E, Macolino C, Mahlstedt J, Manfredini A, Marignetti F, Marrodán Undagoitia T, Masbou J, Mastroianni S, Messina M, Micheneau K, Miller K, Molinario A, Morå K, Mosbacher Y, Murra M, Naganoma J, Ni K, Oberlack U, Odgers K, Palacio J, Pelssers B, Peres R, Pienaar J, Pizzella V, Plante G, Podviianiuk R, Qin J, Qiu H, Ramírez García D, Reichard S, Riedel B, Rocchetti A, Rupp N, Dos Santos JMF, Sartorelli G, Šarčević N, Scheibelhut M, Schindler S, Schreiner J, Schulte D, Schumann M, Scotto Lavina L, Selvi M, Shagin P, Shockley E, Silva M, Simgen H, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Upole N, Vargas M, Volta G, Wack O, Wang H, Wei Y, Weinheimer C, Wenz D, Wittweg C, Wulf J, Ye J, Zhang Y, Zhu T, Zopounidis JP. Light Dark Matter Search with Ionization Signals in XENON1T. PHYSICAL REVIEW LETTERS 2019; 123:251801. [PMID: 31922764 DOI: 10.1103/physrevlett.123.251801] [Show More Authors] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 11/07/2019] [Indexed: 06/10/2023]
Abstract
We report constraints on light dark matter (DM) models using ionization signals in the XENON1T experiment. We mitigate backgrounds with strong event selections, rather than requiring a scintillation signal, leaving an effective exposure of (22±3) tonne day. Above ∼0.4 keV_{ee}, we observe <1 event/(tonne day keV_{ee}), which is more than 1000 times lower than in similar searches with other detectors. Despite observing a higher rate at lower energies, no DM or CEvNS detection may be claimed because we cannot model all of our backgrounds. We thus exclude new regions in the parameter spaces for DM-nucleus scattering for DM masses m_{χ} within 3-6 GeV/c^{2}, DM-electron scattering for m_{χ}>30 MeV/c^{2}, and absorption of dark photons and axionlike particles for m_{χ} within 0.186-1 keV/c^{2}.
Collapse
|
|
6 |
67 |
13
|
|
Comment |
28 |
66 |
14
|
Abe K, Abgrall N, Ajima Y, Aihara H, Albert JB, Andreopoulos C, Andrieu B, Aoki S, Araoka O, Argyriades J, Ariga A, Ariga T, Assylbekov S, Autiero D, Badertscher A, Barbi M, Barker GJ, Barr G, Bass M, Bay F, Bentham S, Berardi V, Berger BE, Bertram I, Besnier M, Beucher J, Beznosko D, Bhadra S, Blaszczyk FDMM, Blondel A, Bojechko C, Bouchez J, Boyd SB, Bravar A, Bronner C, Brook-Roberge DG, Buchanan N, Budd H, Calvet D, Cartwright SL, Carver A, Castillo R, Catanesi MG, Cazes A, Cervera A, Chavez C, Choi S, Christodoulou G, Coleman J, Coleman W, Collazuol G, Connolly K, Curioni A, Dabrowska A, Danko I, Das R, Davies GS, Davis S, Day M, De Rosa G, de André JPAM, de Perio P, Delbart A, Densham C, Di Lodovico F, Di Luise S, Dinh Tran P, Dobson J, Dore U, Drapier O, Dufour F, Dumarchez J, Dytman S, Dziewiecki M, Dziomba M, Emery S, Ereditato A, Escudero L, Esposito LS, Fechner M, Ferrero A, Finch AJ, Frank E, Fujii Y, Fukuda Y, Galymov V, Gannaway FC, Gaudin A, Gendotti A, George MA, Giffin S, Giganti C, Gilje K, Golan T, Goldhaber M, Gomez-Cadenas JJ, Gonin M, Grant N, Grant A, Gumplinger P, et alAbe K, Abgrall N, Ajima Y, Aihara H, Albert JB, Andreopoulos C, Andrieu B, Aoki S, Araoka O, Argyriades J, Ariga A, Ariga T, Assylbekov S, Autiero D, Badertscher A, Barbi M, Barker GJ, Barr G, Bass M, Bay F, Bentham S, Berardi V, Berger BE, Bertram I, Besnier M, Beucher J, Beznosko D, Bhadra S, Blaszczyk FDMM, Blondel A, Bojechko C, Bouchez J, Boyd SB, Bravar A, Bronner C, Brook-Roberge DG, Buchanan N, Budd H, Calvet D, Cartwright SL, Carver A, Castillo R, Catanesi MG, Cazes A, Cervera A, Chavez C, Choi S, Christodoulou G, Coleman J, Coleman W, Collazuol G, Connolly K, Curioni A, Dabrowska A, Danko I, Das R, Davies GS, Davis S, Day M, De Rosa G, de André JPAM, de Perio P, Delbart A, Densham C, Di Lodovico F, Di Luise S, Dinh Tran P, Dobson J, Dore U, Drapier O, Dufour F, Dumarchez J, Dytman S, Dziewiecki M, Dziomba M, Emery S, Ereditato A, Escudero L, Esposito LS, Fechner M, Ferrero A, Finch AJ, Frank E, Fujii Y, Fukuda Y, Galymov V, Gannaway FC, Gaudin A, Gendotti A, George MA, Giffin S, Giganti C, Gilje K, Golan T, Goldhaber M, Gomez-Cadenas JJ, Gonin M, Grant N, Grant A, Gumplinger P, Guzowski P, Haesler A, Haigh MD, Hamano K, Hansen C, Hansen D, Hara T, Harrison PF, Hartfiel B, Hartz M, Haruyama T, Hasegawa T, Hastings NC, Hastings S, Hatzikoutelis A, Hayashi K, Hayato Y, Hearty C, Helmer RL, Henderson R, Higashi N, Hignight J, Hirose E, Holeczek J, Horikawa S, Hyndman A, Ichikawa AK, Ieki K, Ieva M, Iida M, Ikeda M, Ilic J, Imber J, Ishida T, Ishihara C, Ishii T, Ives SJ, Iwasaki M, Iyogi K, Izmaylov A, Jamieson B, Johnson RA, Joo KK, Jover-Manas GV, Jung CK, Kaji H, Kajita T, Kakuno H, Kameda J, Kaneyuki K, Karlen D, Kasami K, Kato I, Kearns E, Khabibullin M, Khanam F, Khotjantsev A, Kielczewska D, Kikawa T, Kim J, Kim JY, Kim SB, Kimura N, Kirby B, Kisiel J, Kitching P, Kobayashi T, Kogan G, Koike S, Konaka A, Kormos LL, Korzenev A, Koseki K, Koshio Y, Kouzuma Y, Kowalik K, Kravtsov V, Kreslo I, Kropp W, Kubo H, Kudenko Y, Kulkarni N, Kurjata R, Kutter T, Lagoda J, Laihem K, Laveder M, Lee KP, Le PT, Levy JM, Licciardi C, Lim IT, Lindner T, Litchfield RP, Litos M, Longhin A, Lopez GD, Loverre PF, Ludovici L, Lux T, Macaire M, Mahn K, Makida Y, Malek M, Manly S, Marchionni A, Marino AD, Marteau J, Martin JF, Maruyama T, Maryon T, Marzec J, Masliah P, Mathie EL, Matsumura C, Matsuoka K, Matveev V, Mavrokoridis K, Mazzucato E, McCauley N, McFarland KS, McGrew C, McLachlan T, Messina M, Metcalf W, Metelko C, Mezzetto M, Mijakowski P, Miller CA, Minamino A, Mineev O, Mine S, Missert AD, Mituka G, Miura M, Mizouchi K, Monfregola L, Moreau F, Morgan B, Moriyama S, Muir A, Murakami A, Murdoch M, Murphy S, Myslik J, Nakadaira T, Nakahata M, Nakai T, Nakajima K, Nakamoto T, Nakamura K, Nakayama S, Nakaya T, Naples D, Navin ML, Nelson B, Nicholls TC, Nishikawa K, Nishino H, Nowak JA, Noy M, Obayashi Y, Ogitsu T, Ohhata H, Okamura T, Okumura K, Okusawa T, Oser SM, Otani M, Owen RA, Oyama Y, Ozaki T, Pac MY, Palladino V, Paolone V, Paul P, Payne D, Pearce GF, Perkin JD, Pettinacci V, Pierre F, Poplawska E, Popov B, Posiadala M, Poutissou JM, Poutissou R, Przewlocki P, Qian W, Raaf JL, Radicioni E, Ratoff PN, Raufer TM, Ravonel M, Raymond M, Retiere F, Robert A, Rodrigues PA, Rondio E, Roney JM, Rossi B, Roth S, Rubbia A, Ruterbories D, Sabouri S, Sacco R, Sakashita K, Sánchez F, Sarrat A, Sasaki K, Scholberg K, Schwehr J, Scott M, Scully DI, Seiya Y, Sekiguchi T, Sekiya H, Shibata M, Shimizu Y, Shiozawa M, Short S, Siyad M, Smith RJ, Smy M, Sobczyk JT, Sobel H, Sorel M, Stahl A, Stamoulis P, Steinmann J, Still B, Stone J, Strabel C, Sulak LR, Sulej R, Sutcliffe P, Suzuki A, Suzuki K, Suzuki S, Suzuki SY, Suzuki Y, Suzuki Y, Szeglowski T, Szeptycka M, Tacik R, Tada M, Takahashi S, Takeda A, Takenaga Y, Takeuchi Y, Tanaka K, Tanaka HA, Tanaka M, Tanaka MM, Tanimoto N, Tashiro K, Taylor I, Terashima A, Terhorst D, Terri R, Thompson LF, Thorley A, Toki W, Tomaru T, Totsuka Y, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Ueno K, Vacheret A, Vagins M, Vasseur G, Wachala T, Walding JJ, Waldron AV, Walter CW, Wanderer PJ, Wang J, Ward MA, Ward GP, Wark D, Wascko MO, Weber A, Wendell R, West N, Whitehead LH, Wikström G, Wilkes RJ, Wilking MJ, Wilson JR, Wilson RJ, Wongjirad T, Yamada S, Yamada Y, Yamamoto A, Yamamoto K, Yamanoi Y, Yamaoka H, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Zalewska A, Zalipska J, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. Indication of electron neutrino appearance from an accelerator-produced off-axis muon neutrino beam. PHYSICAL REVIEW LETTERS 2011; 107:041801. [PMID: 21866992 DOI: 10.1103/physrevlett.107.041801] [Show More Authors] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Indexed: 05/31/2023]
Abstract
The T2K experiment observes indications of ν(μ) → ν(e) appearance in data accumulated with 1.43×10(20) protons on target. Six events pass all selection criteria at the far detector. In a three-flavor neutrino oscillation scenario with |Δm(23)(2)| = 2.4×10(-3) eV(2), sin(2)2θ(23) = 1 and sin(2)2θ(13) = 0, the expected number of such events is 1.5±0.3(syst). Under this hypothesis, the probability to observe six or more candidate events is 7×10(-3), equivalent to 2.5σ significance. At 90% C.L., the data are consistent with 0.03(0.04) < sin(2)2θ(13) < 0.28(0.34) for δ(CP) = 0 and a normal (inverted) hierarchy.
Collapse
|
|
14 |
65 |
15
|
Messina M, Lampe JW, Birt DF, Appel LJ, Pivonka E, Berry B, Jacobs DR. Reductionism and the narrowing nutrition perspective: time for reevaluation and emphasis on food synergy. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION 2001; 101:1416-9. [PMID: 11762736 DOI: 10.1016/s0002-8223(01)00342-x] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
Review |
24 |
64 |
16
|
Abstract
Soyfoods have received considerable attention during the past 5 years for their role in disease prevention, especially in relation to heart disease, osteoporosis, and cancer. However, limited research also suggests that soy protein favorably affects renal function. Much of the research interest in soy is aimed at establishing the physiological effects of isoflavones. Isoflavones are diphenolic compounds that have a very limited distribution in nature. Soybeans and soyfoods are, for practical purposes, the only nutritionally relevant dietary sources of isoflavones. Isoflavones are weak estrogens in that they bind to estrogen receptors, but they also have important nonhormonal properties as well. Initial speculation that soyfoods, and in particular isoflavones, might promote bone health was based on the estrogenic properties of isoflavones and the similarity in structure between isoflavones and the osteoporosis drug, ipriflavone, which is a synthetic isoflavone. In ovariectomized rodents, isoflavones retard bone loss almost as effectively as estrogen. Most research, but not all, also indicates that soyfoods rich in isoflavones favorably affect bone turnover and spinal bone mineral density in perimenopausal and postmenopausal women. However, studies conducted thus far have been of short duration and involved small numbers of subjects. Furthermore, no studies have actually examined the effect of soy feeding on fracture risk. Thus, although the data in general are encouraging, no firm conclusions can be drawn about the relationship between soy consumption and bone health. In addition to a possible direct effect of isoflavones on bone tissue, soy protein when substituted for animal protein may indirectly enhance bone strength. Several studies have found that in comparison with animal protein, soy protein decreases calcium excretion, a result of the lower sulfur amino acid content of soy protein. Although the high potassium content of soy is a consideration, the evidence clearly indicates that clinicians should consider recommending that their renal patients incorporate soyfoods into their diet.
Collapse
|
Review |
25 |
64 |
17
|
Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, Ravdin P, Brown M, Messina M, Tuck D, Weil C, Winograd B. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 2001; 12:1067-73. [PMID: 11583187 DOI: 10.1023/a:1011655503511] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND To determine the cardiotoxicity of paclitaxel (T) plus doxorubicin (A) combination therapy in women with advanced breast cancer. To define a dose range of A for use in AT. PATIENTS AND METHODS The effect of cumulative A dose on risk of congestive heart failure (CHF) and alterations of myocardial contractility (left ventricular ejection fraction [LVEF] decrease > or = 20% or to <50%) was estimated from pooled data from 10 trials of AT. RESULTS Thirty-one of 657 patients (4.7%) developed CHF at a median of 6.6 months (range 0.3-24.6) after initiation of AT. CHF was stabilized in 29 patients at a median of 17.3 months after diagnosis (range 4.1-31.2 months). The risk of developing CHF was < or = 5% at a total A dose < or = 380 mg/m2. In patients who received a total A dose > 440 mg/m2, the incidence of CHF was >25% but similar to that of A monotherapy. The risk of CHF was similar in women receiving AT or A monotherapy at a dose < or = 380 mg/m2 (2%-3%). LVEF progressively decreased in patients who received AT, especially at a cumulative A dose > 380 mg/m2. LVEF decreases were more frequent in patients who later developed CHF, but the majority of CHF patients did not experience LVEF alterations prior to symptoms. LVEF recovered after discontinuation of A in 25 of 67 women who developed LVEF < 50%. CONCLUSION The reported cardiac effects are consistent with anthracycline-related cardiotoxicity. AT is associated with a cardiac risk similar to that of A monotherapy up to a cumulative A dose of 340-380 mg/m2.
Collapse
|
|
24 |
64 |
18
|
|
|
26 |
61 |
19
|
Lavacca A, Presta R, Gai C, Mella A, Gallo E, Camussi G, Abbasciano I, Barreca A, Caorsi C, Fop F, Messina M, Rossetti M, Biancone L. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant 2020; 34:e13908. [PMID: 32415711 DOI: 10.1111/ctr.13908] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 05/09/2020] [Accepted: 05/09/2020] [Indexed: 01/01/2023]
Abstract
INTRODUCTION Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has been recently used as rescue therapy in patients non-responsive to rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts "per se" or requires a priming effect from previous treatments is currently unknown. METHODS Fifteen patients with cAMR were treated with TCZ as a first-line therapy and followed for a median time of 20.7 months. RESULTS Despite the majority of patients experiencing advanced transplant glomerulopathy (TG) at diagnosis (60% with cg3), glomerular filtration rate and proteinuria stabilized during the follow-up, with a significant reduction in donor-specific antibodies. Protocol biopsies after 6 months demonstrated significant amelioration of microvascular inflammation and no TG, C4d deposition, or IF/TA progression. Gene-expression and immunofluorescence analysis showed upregulation of three genes (TJP-1, AKR1C3, and CASK) involved in podocyte, mesangial, and tubular restoration. CONCLUSION Tocilizumab adopted as a first-line approach in cAMR was associated with early serological and histological improvements and functional stabilization even in advanced TG, suggesting a role for the use of TCZ alone with the avoidance of unnecessary previous immunosuppressants.
Collapse
|
Research Support, Non-U.S. Gov't |
5 |
57 |
20
|
Robinson DS, Alms DR, Shrotriya RC, Messina M, Wickramaratne P. Serotonergic anxiolytics and treatment of depression. Psychopathology 1989; 22 Suppl 1:27-36. [PMID: 2657837 DOI: 10.1159/000284624] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The serotonin 5-hydroxytryptamine-1A (5-HT1A) receptor agonists buspirone and gepirone have effects on serotonergic systems, including presynaptic and postsynaptic receptors, that predict both anxiolytic and antidepressant activity. Chronic administration of both drugs produces a down-regulation of 5-HT2 receptors, a finding common to most antidepressant drugs irrespective of mechanism of action. In addition, gepirone induces a full-blown serotonin syndrome in rodents and is active in the behavioral despair test mediated by an action on serotonergic neurons. Buspirone is active in this paradigm when injected directly into the serotonergic dorsal raphe nucleus. The therapeutic effects of both buspirone and gepirone have been assessed in placebo-controlled studies of patients with major depression. Findings in these studies support antidepressant efficacy in addition to anxiolysis. In double-blind studies of patients with major depression treated for 8 weeks, each drug was found to be superior to placebo in improvement in Hamilton Depression and Anxiety total scores as well as individual depressive symptoms. These clinical findings are consistent with preclinical pharmacology suggesting that 5-HT1A partial agonists may possess intrinsic antidepressant activity.
Collapse
|
Clinical Trial |
36 |
55 |
21
|
Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008; 31:866-72. [PMID: 19092290 DOI: 10.1007/bf03346433] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Antithyroid drugs may be proposed as the firstline therapy for hyperthyroidism due to Graves' disease since some patients undergo prolonged remission after drug withdrawal. On the other hand, some studies, though controversial, indicated that methimazole (MMI) has some immunomodulating activity. We retrospectively analyzed 384 consecutive patients newly diagnosed with Graves' disease in the years 1990-2002 to ascertain whether long-term therapy with low doses of MMI may prevent relapse of thyrotoxicosis. Two hundred and forty-nine patients were included in our study. The date of reduction of MMI dose to 5 mg/day was considered time 0 for survival analysis. In 121 MMI was discontinued in less than 15 months after time 0 (group D), while in the remaining 128 a daily MMI 2.5-5 mg dose was maintained (group M). One hundred and thirty-five patients were excluded for inadequate response to MMI, relapse of thyrotoxicosis that could be related to an improper withdrawal or reduction of MMI, inadequate or too short followup, iodide contamination, steroid or interferon therapy, pregnancy or post-partum. D and M groups did not differ for clinical and hormonal parameters except age, which was lower in D (p=0.019). Age > vs < 35 yr was relevant in survival analysis; therefore patients were divided in 2 groups according to this age cut-off. In younger patients relapse of thyrotoxicosis occurred in 15 patients of group D 2.4-39.6 months (median 19.0) after time 0, and 8 M after 5.9-40.0 (21.3) months, while 14 D and 5 M maintained euthyroidism until the end of the observation after 31.8-95.3 (56.6) months and 30.4-62.1 (46.5) months, respectively. Survival analysis indicated that the risk of relapse was similar in group D and M. In older patients relapse of thyrotoxicosis occurred in 40 patients of group D after 8.2-65.8 (25.4) months and 29 M after 5.8-62.5 (22.4) months, while 52 D and 86 M maintained euthyroidism until the end of the observation, 20.1-168.0 (46.7) months and 24.1-117.4 (53.4) months respectively. Survival analysis indicated that the risk of relapse was increased in group D. Therefore long-term treatment with low doses of MMI seems to prevent relapse in Graves' disease in patients above 35 yr of age. This should be confirmed in a prospective study.
Collapse
|
Comparative Study |
17 |
55 |
22
|
Miroballi Y, Baird JS, Zackai S, Cannon JM, Messina M, Ravindranath T, Green R, Della-Latta P, Jenkins S, Greenwald BM, Furuya EY, Graham PL, Sonnett FM, Platt S, Delamora P, Saiman L. Novel influenza A(H1N1) in a pediatric health care facility in New York City during the first wave of the 2009 pandemic. ACTA ACUST UNITED AC 2010; 164:24-30. [PMID: 20048238 DOI: 10.1001/archpediatrics.2009.259] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVE To describe the burden of care experienced by our pediatric health care facility in New York, New York, from May 3, 2009, to July 31, 2009, during the novel influenza A(H1N1) pandemic that began in spring 2009. DESIGN Retrospective case series. SETTING Pediatric emergency departments and inpatient facilities of New York-Presbyterian Hospital. Patients Children presenting to the emergency departments with influenza-like illness (ILI) and children aged 18 years or younger hospitalized with positive laboratory test results for influenza A from May 3, 2009, to July 31, 2009. MAIN OUTCOME MEASURES Proportion of children with ILI who were hospitalized and proportion of hospitalized children with influenza A with respiratory failure, bacterial superinfection, and mortality. RESULTS When compared with the same period in 2008, the pediatric emergency departments experienced an excess of 3750 visits (19.9% increase). Overall, 27.7% of visits were for ILI; 2.5% of patients with ILI were hospitalized. Of the 115 hospitalized subjects with confirmed influenza A (median age, 4.3 years), 93 (80.9%) had underlying conditions. Four (3.5%) had identified bacterial superinfection, 1 (0.9%) died, and 35 (30.4%) were admitted to a pediatric intensive care unit; of these 35 patients, 11 had pneumonia and required mechanical ventilation, including high-frequency oscillatory ventilation (n = 3). CONCLUSIONS At our center, 2.5% of children with ILI presenting to the emergency departments during the first wave of the 2009 novel influenza A(H1N1) pandemic were hospitalized. Of the 115 hospitalized children with confirmed influenza A, 9.6% had respiratory failure and 0.9% died. These findings can be compared with the disease severity of subsequent waves of the 2009 novel influenza A(H1N1) pandemic.
Collapse
|
Multicenter Study |
15 |
53 |
23
|
Flecchia D, Mazza E, Carlini M, Blatto A, Olivieri F, Serra G, Camanni F, Messina M. Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour. Clin Endocrinol (Oxf) 1995; 42:129-34. [PMID: 7704956 DOI: 10.1111/j.1365-2265.1995.tb01852.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND AND OBJECTIVE Reduced serum levels of dehydroepiandrosterone sulphate (DHEAS) have been shown in patients with Cushing's syndrome resulting from adrenocortical adenoma, in contrast with normal DHEAS levels in patients with Cushing's disease. The aim of this study was to verify whether patients with incidentally discovered adrenocortical adenomas also have reduced levels of DHEAS. DESIGN Evaluation of serum DHEAS, serum and urinary cortisol, plasma ACTH and low dose dexamethasone suppression test in patients with adrenal incidentaloma and Cushing's syndrome. PATIENTS Thirty-two patients with adrenal incidentaloma and, as controls, 17 patients with overt Cushing's syndrome, were studied. RESULTS Serum DHEAS levels lower than normal were found in 21/24 (87.5%) patients with adrenocortical incidentaloma, but in only 1/8 patients with a mass of non-adrenocortical origin. This patient had massive bilateral metastatic infiltration of both adrenal glands and primary adrenal failure. The prevalence of low DHEAS levels in the two groups was significantly different (P = 0.0001). In patients with adrenocortical incidentaloma, the prevalence of low DHEAS levels was significantly higher (P = 0.0001) than that found for some hormonal alterations indicating pre-clinical hypercortisolism (high urinary cortisol, unsuppressed serum cortisol after low dose dexamethasone administration and low plasma ACTH). Low DHEAS levels were found in all patients with Cushing's syndrome due to adrenocortical adenoma but in none of those with Cushing's disease. CONCLUSIONS Our results indicate that the finding of low DHEAS levels can be considered a marker of the adrenocortical origin of an adrenal incidentaloma, provided adrenal failure has been excluded.
Collapse
|
|
30 |
51 |
24
|
Scichilone N, Messina M, Battaglia S, Catalano F, Bellia V. Airway hyperresponsiveness in the elderly: prevalence and clinical implications. Eur Respir J 2005; 25:364-75. [PMID: 15684304 DOI: 10.1183/09031936.05.00080204] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Airway hyperresponsiveness is associated with an increased risk of developing respiratory symptoms. The assessment of airway hyperresponsiveness can provide valuable information regarding the natural course of respiratory diseases. However, little information is available for populations of more advanced age, and data are conflicting. It was assessed whether age influences the occurrence of airway hyperresponsiveness by reviewing those studies that specifically addressed this issue, and attempting to identify the factors responsible for discrepancies between studies. Eighteen studies, published between 1983 and 2002, are included in this review. Overall, the results of the analysis are in favour of a positive association between age and airway hyperresponsiveness, the prevalence of which appears to increase in the elderly. The most important determinants were reduced lung function, probably due to geometric factors, and a history of smoking, primarily because of the length of exposure, although acute effects were also demonstrated. Atopy should also be considered as an independent determinant of airway hyperresponsiveness in the elderly population. In addition, inflammatory and neuronal mechanisms could be involved. Finally, the role of sex requires further investigation. Assessing the impact of age on the occurrence of airway hyperresponsiveness has important implications: the age-associated alterations to the lung provide a model for evaluating the contribution of structural changes to the pathogenesis of airway hyperresponsiveness. From a clinical standpoint, evaluation of the magnitude of airway hyperresponsiveness could permit the early identification of individuals who are at risk, even at more advanced age. Assessment of airway hyperresponsiveness in the aged should be considered as an additional tool in the diagnostic work-up in the subset of elderly subjects with long-term smoking exposure and/or documented atopy.
Collapse
|
Review |
20 |
47 |
25
|
Messina M. Soyfoods and soybean phyto-oestrogens (isoflavones) as possible alternatives to hormone replacement therapy (HRT). Eur J Cancer 2000; 36 Suppl 4:S71-2. [PMID: 11056326 DOI: 10.1016/s0959-8049(00)00233-1] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
|
25 |
46 |